Covered recipient · General Payments record
ANAN AFANEH
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$1,581.85
- Reported across 103 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $312.72 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $174.47 | 13 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $89.20 | 3 |
| ABBVIE INC. | $29.55 | 1 |
| E.R. Squibb & Sons, L.L.C. | $19.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $29.55 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103177852 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.50 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101356032 | CMS |
| Novartis Pharmaceuticals Corporation | $29.49 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086739477 | CMS |
| Novartis Pharmaceuticals Corporation | $29.48 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086739479 | CMS |
| Novartis Pharmaceuticals Corporation | $30.23 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086739495 | CMS |
| PFIZER INC. | $28.13 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130896312 | CMS |
| PFIZER INC. | $20.17 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130902958 | CMS |
| PFIZER INC. | $9.39 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130934207 | CMS |
| PFIZER INC. | $7.91 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130934195 | CMS |
| PFIZER INC. | $5.82 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130935671 | CMS |
| PFIZER INC. | $3.47 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130931513 | CMS |
| PFIZER INC. | $16.85 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130924235 | CMS |
| PFIZER INC. | $2.75 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130931943 | CMS |
| PFIZER INC. | $22.65 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130929780 | CMS |
| PFIZER INC. | $17.33 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130948757 | CMS |
| PFIZER INC. | $1.77 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130939520 | CMS |
| PFIZER INC. | $28.82 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130983899 | CMS |
| PFIZER INC. | $9.41 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131059862 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.